KRAS G12C

Oncology

17 drugs in development·7 companies·6 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
krazati	Mirati Therapeutics, Inc. (MRTX)
krazati	BRISTOL MYERS SQUIBB CO (BMY)

Phase 3(4)

Phase 2(3)

Phase 1(1)

Drug	Company
ko-2806	Kura Oncology, Inc. (KURA)

Preclinical(1)

Drug	Company
fyarro + adagrasib	Whitehawk Therapeutics, Inc. (WHWK)

Phase 1/Phase 2(6)

BioSniper tracks 17 drugs in development for KRAS G12C across 7 companies.

There are 6 clinical trials targeting KRAS G12C tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.